(between-run imprecision) is 10-17%. Analytical recovery is 80-90%, and C-terminal parathyrin measured in fresh sera and in sera stored for seven days at 30 #{176}C is equivalent.
AddItIonal KeyphraSes: reference intervals parathyroid disorders ' hormones ' disorders of calcium regulation
Parathyrin
(parathyroid hormone, PTH) is an 84-aminoacid polypeptide (relative molecular mass 9500) normally produced and released by the parathyroid glands in response to changing serum calcium status (1) . Pro-PTH and prepro-PTH are also formed in the glands but cannot be detected in the circulation (2) . Intact PTH (amino acids 1-84) is cleaved both within the gland and in the periphery (3) to form N-terminal (amino acids 1-34; N-PTH) and C-terminal fragments (4) . The biological half-lives of these fragments are less than 5 mm and 40 mm, respectively, before further metabolism and excretion by the kidney (5) . Only the N-PTH fragment and the intact hormone are biologically active (6) .
Measurement of N-PTH reportedly is of value in observing acute responses to serum calcium changes and after venous catheterization of the neck in an attempt to localize the site of hyperfunctioning glands (7) . Serum or plasma C-PTH activity has been used to diagnose primary hyperparathyroidism, to follow parathyroid response in chronic renal failure, and to aid in differential diagnosis of other hypercalcemic and hypocalcemic disorders (8, 9) .
A controversy regarding the appropriate use of N-PTH and C-PTH assays in patient management has not been fully resolved, partly because of the overlap observed in PTH results obtained for groups of patients believed to be clinically distinct (8, 10, 11) . Thus, accurate and precise assays are required clinically.
In developing the present assay to meet these requirements, we have used only reagents available through common commercial sources.
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Materials and Methods

Reagent and Standard Preparation Procedures
Buffer. Dissolve 5.89 g of sodium barbital, 3.89 g of sodium acetate, 6.8 g of sodium chloride, and 110.0 g of polyethylene glycol (no. 6103, average Mr 7500; Polysciences, Inc., Warrington, PA 18976) in 950 mL of distilled water in a 1-L volumetric flask. Add 25 mL of aprotinin (Trasylol, 10 000 Kal- Wash the pellet with 1 mL of freshly mixed acetone/acetic acid (2 mL of acetone is added to 8 mL of a 10 mL/L solution of acetic acid). With a gamma counter, count the radioactivity of a 0.3-mL aliquot of a 100-fold dilution of the 1251-labeled PTH with serum buffer, and calculate the appropriate dilution to provide 60 pg of PTH per 0.3 mL of serum buffer as follows: Average each triplicate set of standard concentrations, subtract the nonspecific counts, and divide each by the zero binding counts (B0) to obtain B/B0. Plot logit-log of B/B0 vs concentration.
Calculate B/B0 of samples and pools by averaging the duplicate bound counts, subtracting the nonspecific counts determined for each sample, and dividing by the zero binding. Obtain PTH concentration in samples and pools by comparing B/B0 with the plotted standard curve.
Serum Calcium
We assayed calcium by atomic absorption spectroscopy (15) . Figure 2 ) without substantially affecting zero binding (B0). The present assay requires a one-day preincubation before tracer is added, followed by a three-day incubation with tracer. As shown in Figure 3 , shortening the second incubation to one day reduces the zero binding from 26% to 15% and results in a relatively flat standard curve. Omitting the preincubation step (without tracer) decreases label displacement by the standards or samples and thus causes a loss in sensitivity.
Results
The detection limit of the present assay is 250 ng/L (500 mt. In spite of our vigorous efforts to control quality of iodinations, occasional aliquots show high nonspecific binding. These "impure" tracers produce severe deviation of sample and pool results from the standard curve and require a repeat analysis with a new aliquot of tracer. The effect of such a tracer on the assay characteristics is shown in Table 1 . These problems are overcome by using the daily tracer re-purification procedure as described in Methods and Materials. Figure 4 shows the results of cellulose acetate electrophoresis of an "impure" tracer before and after re-purification with silica. The impurity showing radioactivity in fraction 7 contributes about 6% of the total counts and is removed by the purification. Table 2 shows the within-run and overall precision of the C-PTH assay, as determined by including two to four aliquots of each pool (in duplicate) in seven independent batches over a four-month period. Within-run variation (CV) ranged from 3.6 to 8.5%; overall CV was less than 10% except in the lowconcentration pool, for which it was 17.2%. Analytical recovery of PTH in the assay is 80-90%, in pools fortified with the same intact bovine hormone used as a standard.
Storage of the quality-control pools (including some fortified pools) either for two months at 4 #{176}C or frozen for at least one year resulted in no systematic drift in results, indicating that C-PTH stability was not compromised. Serum is apparently the most appropriate matrix for this particular C-PTH assay. Table 3 shows results for serum and heparin-and EDTA-treated plasma samples, each obtained A straightforward demonstration of this point is possible because of the commercial availability of synthetic N-PTH fragments in the bovine amino acid sequence ( Figure  1 ). An absence of N-PTH cross-reactivity with the present antibody is not unexpected because the antibody used is reported to be raised to bovine PTH conjugated at the N-ter- with intact hormone as standard and label should be higher by the C-assay than by an N-assay. This characteristic is based on the reported longer half-life of the C-PTH species. As shown in Figure 6 , the adult reference range of the present assay is higher than N-PTH ranges reported (11).
Seve n Independent Batches
4. An as yet unpublished characteristic of C-PTH suggested recently (D. C. Arnaud, Veterans Administration, San Francisco, CA 94121) is its increased stability over that of N-PTH or intact PTH. Stability of C-PTH has been demonstrated in normal sera for at least seven days at 30#{176}C with the present C-PTH assay. In contrast, assays for measuring N-PTH or intact PTH require frozen storage or fresh samples.
5. Finally, the most relevant criterion for any PTH assay is its clinical utility. Because screening PTH antibodies with patients' samples is impractical, investigators have attempted to relate cross-reactivity results to the ability of PTH antibodies to discriminate among clinical groups. Recently, the validity of this practice has been questioned (10) . In an accompanying paper (this issue), we present results of a small clinical study involving the antibody described in this paper;
this assay, combined with serum calcium determination, shows good discrimination between hypoparathyroid patients, healthy adults, patients with primary and secondary hyperparathyroidism, and patients with non-parathyroid malignancy.
We used intact bovine PTH to prepare the tracer and standard curve in the present assay. Although various standard materials have been used in other PTH assays, the intact bovine hormone has both theoretical and practical advantages.
Two heterogeneities exist in the present assay: (a) in the use of bovine label/standard in measuring human samples (het-erology in assay technique) and (b) in the proven heterogeneity of circulating molecules with C-terminal sequences. At least two different C-terminal fragments (Mr 7000 and 4500) have been reported in addition to the intact molecule (Mr 9500), which also contains the C-terminal sequence (4) . The proportions of these species differ markedly in different clinical situations and also among patients with the same diagnosis (3, 4, 19, 20) . An extreme point of view would demand that four to six separate assays be offered for PTH, each with its own human-derived standards (and iodinated tracers) for each clinical group, but no practical necessity for such extremes has yet been demonstrated.
Buckle (21) has suggested that the best compromise is to use a standard that is common to all groups, i.e., the intact hormone as in the present assay. He also states that an assay involving hyperparathyroid serum standards should not be applied to samples from patients with malignancy or renal-failure because of the differing proportions of circulating PTH fragments.
C-PTH assays have been described in which dilutions of a hyperparathyroid serum or plasma pool are used as the working standard (8, 10, 18) . In these assays, a patient's results are reported in microliter equivalent units, i.e., the microliter amount of the "standard" serum or plasma found to give the same B/B0 as the patient's sample. In addition to the theoretical objections to using hyperparathyroid sera as assay standards, several practical problems arise-such as (a) the influence on the assay of changing serum sources (inter-patient heterogeneity), (b) stability of raw serum over long periods, (c) difficulty in obtaining a representative source, and (d) lack of calibration-which preclude any mnterlaboratory comparison. We used purified bovine intact hormone in the present assay because human hormones
have not yet been reliably produced in sufficient quantity and because the cross reactivity between human and bovine intact PTH has been found by several different investigators to be high (10, 14) . The present assay is maintained in calibration with the World Health Organization First International Reference Preparation.
The optimal timing of incubation with the present antibody from CIS Radiopharmaceuticals is the sequential system described in Methods and Materials.
Most C-PTH assays reported (4,8, 10, 16, Figure 3 .
The effect of incubation pH on the assay is important, not only because of the potential effect of laboratory errors but also because of reports that PTH changes conformation at alkaline pH (22) and that binding of N-PTH by antibodies may be increased at acid pH (23) . Several other C-PTH assays are reported at pH 8.4 (4, 10, 12, 16, 18) , whereas the present method is pH 7.4. The standard curves shown in Figure 2 we compared results for clinical samples at different incubation pH; discrimination among groups was better at pH 7.4 than at 8.4. Therefore, pH 7.4 appears to be optimal for the present antibody.
After questions of antibody characterization, standardization materials, and buffer composition are resolved, PTH assays may still be perturbed by erratic behavior of the iodinated hormone (14, 16, 21) . A brief tracer re-purification procedure with QUSO increased the ruggedness of the assay, not only when the tracer was clearly contaminated but also in marginal batches without obvious tracer-related problems. The re-purification procedure requires approximately 30 mm and, to be effective, should be freshly done before the iodinated tracer is used.
The stability of C-PTH at 30 #{176}C for seven days ( Figure 5) is somewhat unexpected in view of the documented instability of intact PTH and N-PTH. However, C-fragments have been reported to be relatively stable in vivo (5). We have not ruled out the possibility that during storage the PTH degraded in the serum to smaller fragments that were equipotent with the intact hormone in displacing tracer. It is convenient, however, that similar results can be obtained from fresh and stored specimens. Working standards in serum buffer give unchanged curves for at least seven days at 4 #{176}C, and pools can be stored for at least two months at 4#{176}C or for six to 12 months at -20 #{176}C.
In summary, the C-PTH assay we describe is a sequential, double-antibody, heterologous system involving antibody raised in rabbits against bovine PTH blocked by conjugation at the N-terminus.
We have characterized the antibody by affinity and cross-reactivity studies. PTH, and all reagents used are available from commercial sources. The antibody requires one-day preincubation with the sample, followed by three days of incubation with the label and 3 h with goat anti-rabbit gamma-globulin for precipitation of bound complex. Assay conditions are designed to ensure accurate calibration, good precision, and high sensitivity. We have examined the components of the incubation buffer and have assured the quality of the iodinated hormone used by the re-purification procedure. The PTH measured in samples is conveniently stable in serum at 30 #{176}C for at least seven days.
